ALIMTA (pemetrexed) and Gemcitabine (gemzar) in Patients with Advanced Cancer
This study is currently recruiting patients.
| Sponsored by: |
Eli Lilly and Company |
| Information provided by: |
Eli Lilly and Company |
Purpose
Phase 1/2 Dose-Escalating Study of Biweekly ALIMTA and Gemcitabine in Patients with Advanced Cancer.
| Condition
|
Treatment or Intervention |
Phase |
Neoplasms
|
Drug: Alimta
Drug: Gemzar
|
Phase I
Phase II
|
MedlinePlus related topics: Cancer; Cancer Alternative Therapy
Study Type: Interventional
Study Design: Treatment
Eligibility
Ages Eligible for Study:
18 Years and above,
Genders Eligible for Study:
Both
Inclusion Criteria:
If you participate in Phase 1 portion of the study
- Have a diagnosis of a solid tumor cancer, including, but not limited to breast, lung, colon, pancreatic, or sarcoma, and can
be treated with chemotherapy.
- May have received prior chemotherapy for your disease, but must not include ALIMTA and GEMZAR.
- Have at least one measurable lesion.
- Have an adequate performance status.
- Sign an informed consent form.
If you participate in Phase 2 portion of the study
- Have a diagnosis of non-small cell lung cancer.
- Have not received prior chemotherapy for your disease.
- Have at least one measurable lesion.
- Have an adequate performance status.
- Sign an informed consent form.
Exclusion Criteria:
- Have been treated with an investigational drug within the last 30 days, have previously completed or withdrawn from this study
or any other study investigating ALIMTA.
- Have received radiation therapy within the last 1-2 weeks.
- Have brain metastasis that is uncontrolled.
- Have active infection or other serious condition.
- Have a second cancer in addition to Advanced Cancer.
Location
and Contact
Information
"There may be multiple sites in this clinical trial".
1-877-CTLILLY (1-877-285-4559)
Minnesota "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY
(1-877-285-4559) or speak with your personal physician"., Minneapolis,
Minnesota,
United States; Recruiting
Texas For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559)
or speak with your personal physician., Dallas,
Texas,
United States; Recruiting
More Information
Study ID Numbers:
7221
Record last reviewed:
February 2004
Record first received:
October 13, 2003
ClinicalTrials.gov Identifier:
NCT00071136Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-10-29
